This disclosure relates to processes for preparing nicotinic acid derivatives that are useful in the chemical arts, such as in the manufacture of pharmaceutical products or agrochemicals. In particular, the present disclosure pertains to novel processes for preparing certain nicotinic acid derivatives.

This disclosure relates to processes for preparing nicotinic acid derivatives that are useful in the chemical arts, such as in the manufacture of pharmaceutical products or agrochemicals. In particular, the present disclosure pertains to novel processes for preparing certain nicotinic acid derivatives.

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

The present invention provides compounds of formula (I): ##STR00001##
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and R.sup.a are as described herein. The present invention relates generally to selective inhibitors of histone deacetylase and to methods of making and using them.

The present invention provides compounds of formula (I): ##STR00001##
or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and R.sup.a are as described herein. The present invention relates generally to selective inhibitors of histone deacetylase and to methods of making and using them.

The present invention provides a method of preventing or treating atherosclerosis or a symptom thereof comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3); or a bispecific inhibitor of neu1 or neu3 of formula I; (I) and a compound of formula I.

##STR00001##

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

In one aspect, the present disclosure provides analogs of thailanstatin of the formula wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.

##STR00001##